{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:45:19Z","timestamp":1794631519685,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Warfarin, like many other anticoagulants, has been linked to an elevated risk of bleeding proportional to the amount of anticoagulation used. Not only was the incidence of bleeding raised by the dosage, but the subtherapeutic international normalized ratio (INR) was also associated with increased thrombotic events. This retrospective cohort and multi-center study evaluated the incidence and risk factors of warfarin therapy complications in community hospitals in Thailand\u2019s central and eastern regions from 2016 to 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 335 patients (683.90 person-year of follow-up), The incidence rate of warfarin complications was 4.91 events per 100 person-year. The independent factor associated with warfarin therapy complications was propranolol prescription (Adjusted RR: 2.29, 95%CI: 1.12\u20134.71). The secondary analysis was divided according to the outcome of the major bleeding and thromboembolic event. Major bleeding events, hypertension (Adjusted RR: 0.40, 95%CI: 0.17\u20130.95), amiodarone prescription (Adjusted RR: 5.11, 95%CI: 1.08\u201324.15), and propranolol prescription (Adjusted RR: 2.86, 95%CI: 1.19\u20136.83) were the independent risk factors. While in the major thrombotic event, non-steroidal anti-inflammatory drugs (NSAIDs) prescription was an independent factor (Adjusted RR: 10.65, 95%CI: 1.26\u201390.35).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-023-06383-2","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T12:02:57Z","timestamp":1686657777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study"],"prefix":"10.1186","volume":"16","author":[{"given":"Benyapha","family":"Sombat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarisa","family":"Tongkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aticha","family":"Nilwaranon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathirut","family":"Mungthin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanlaya","family":"Jongcherdchootrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teeraboon","family":"Lertwanichwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"6383_CR1","doi-asserted-by":"publisher","unstructured":"Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol [Internet]. 2018;268:143\u20138. Available from: https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.034","DOI":"10.1016\/j.ijcard.2018.04.034"},{"key":"6383_CR2","doi-asserted-by":"crossref","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy - antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e44S-e88S.","DOI":"10.1378\/chest.11-2292"},{"key":"6383_CR3","doi-asserted-by":"publisher","unstructured":"Zhao YJ, Lin L, Zhou HJ, Tan KT, Chew AP, Foo CG et al. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol [Internet]. 2016;220:794\u2013801. Available from: https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.087","DOI":"10.1016\/j.ijcard.2016.06.087"},{"key":"6383_CR4","doi-asserted-by":"publisher","unstructured":"Jarungsuccess S, Taerakun S. Cost-utility analysis of oral anticoagulants for Nonvalvular Atrial fibrillation patients at the police general hospital, Bangkok, Thailand. Clin Ther [Internet]. 2014;36(10):1389\u20131394.e4. Available from: https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.016","DOI":"10.1016\/j.clinthera.2014.08.016"},{"key":"6383_CR5","doi-asserted-by":"publisher","unstructured":"Ng SS, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand. Thromb Res [Internet]. 2020;185:63\u201371. Available from: https:\/\/doi.org\/10.1016\/j.thromres.2019.11.012","DOI":"10.1016\/j.thromres.2019.11.012"},{"key":"6383_CR6","unstructured":"Epidemiology C, Hospital MG. an Analysis of the Lowest Effective Intensity of Prophylactic. Hypertension. 1994."},{"key":"6383_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"M Elaine","year":"2006","unstructured":"Elaine M, Hylek MD, Alan MPH, Go S, Yuchiao MD, Chang PhD, Nancy G, Jensvold MPH, Lori E, Henault MPH, Joe V, Selby MD, M.P.H., and, Daniel E, Singer MD. Abstract. Effect of intensity of oral anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"6383_CR8","unstructured":"Br JH. \u2013 2001 - Makris - The management of coumarin-induced over\u2010anticoagulation.pdf."},{"issue":"4","key":"6383_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jacc.2005.09.058","volume":"47","author":"DA Garcia","year":"2006","unstructured":"Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47(4):804\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6383_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/0003-4819-150-5-200903030-00005","volume":"150","author":"MA Crowther","year":"2009","unstructured":"Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Annals of Internal Medicine article oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med. 2009;150:293\u2013300.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6383_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2796.2005.01605.x","volume":"259","author":"AM Njaastad","year":"2006","unstructured":"Njaastad AM, Abildgaard U, Lassen JF. Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med. 2006;259(3):296\u2013304.","journal-title":"J Intern Med"},{"key":"6383_CR12","doi-asserted-by":"publisher","unstructured":"Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest [Internet]. 2005;127(5):1515\u201322. Available from: https:\/\/doi.org\/10.1378\/chest.127.5.1515","DOI":"10.1378\/chest.127.5.1515"},{"issue":"7","key":"6383_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","volume":"118","author":"SD Fihn","year":"1993","unstructured":"Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118(7):511\u201320.","journal-title":"Ann Intern Med"},{"key":"6383_CR14","doi-asserted-by":"publisher","unstructured":"Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis. Int J Cardiol [Internet]. 2013;168(4):4234\u201343. Available from: https:\/\/doi.org\/10.1016\/j.ijcard.2013.07.151","DOI":"10.1016\/j.ijcard.2013.07.151"},{"issue":"2","key":"6383_CR15","first-page":"129","volume":"92","author":"MA Neag","year":"2019","unstructured":"Neag MA, Muntean DM, Nacu A, Catinean A, Farcas A, Vesa S, et al. Influence of concomitant medication on plasma concentration of amiodarone in patients with atrial fibrillation - a pilot study. Med Pharm Reports. 2019;92(2):129\u201333.","journal-title":"Med Pharm Reports"},{"key":"6383_CR16","unstructured":"Patronage, HA of T under the R., King 379 of H.M. the. Thai guideline for warfarin prescription. 2010."},{"issue":"1","key":"6383_CR17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202\u20134.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"6383_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1067\/mjd.2003.47","volume":"48","author":"O Kovich","year":"2003","unstructured":"Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol. 2003;48(2):233\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"6383_CR19","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689\u201396.","journal-title":"Circulation"},{"issue":"5","key":"6383_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jhh.2010.57","volume":"25","author":"LY Ho","year":"2011","unstructured":"Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF. Safety and efficacy of oral anticoagulation therapy in chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens. 2011;25(5):304\u201310.","journal-title":"J Hum Hypertens"},{"issue":"10","key":"6383_CR21","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","volume":"35","author":"TI Shireman","year":"2004","unstructured":"Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362\u20137.","journal-title":"Stroke"},{"issue":"4","key":"6383_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1378\/chest.10-3024","volume":"140","author":"D Poli","year":"2011","unstructured":"Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GYH. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140(4):918\u201324.","journal-title":"Chest"},{"issue":"7","key":"6383_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","volume":"124","author":"D Poli","year":"2011","unstructured":"Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by italian centres for anticoagulation. Circulation. 2011;124(7):824\u20139.","journal-title":"Circulation"},{"issue":"7","key":"6383_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/pds.4781","volume":"28","author":"W Priksri","year":"2019","unstructured":"Priksri W, Rattanavipanon W, Saejear W, Tanyasaensook K, Phrommintikul A, Chulavatnatol S, et al. Incidence, risk factors, and outcomes of warfarin-associated major bleeding in thai population. Pharmacoepidemiol Drug Saf. 2019;28(7):942\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"6383_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5152\/jaem.2013.013","volume":"12","author":"G Altunbas","year":"2013","unstructured":"Altunbas G, Ercan S, Davutoglu V, Al B. Overview of Warfarin treatment and answers to questions. J Acad Emerg Med. 2013;12(1):38\u201342.","journal-title":"J Acad Emerg Med"},{"issue":"5","key":"6383_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2125.1984.tb02390.x","volume":"17","author":"A Scott","year":"1984","unstructured":"Scott A, Park B, Breckenridge A. Interaction between warfarin and propranolol. Br J Clin Pharmacol. 1984;17(5):559\u201364.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"6383_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2125.1984.tb02389.x","volume":"17","author":"N Bax","year":"1984","unstructured":"Bax N, Lennard M, Tucker G, Woods H, Porter N, Malia R, et al. The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. Br J Clin Pharmacol. 1984;17(5):553\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"6383_CR28","unstructured":"Pownall R. Drug interactions and f3 blockers administrator dominated or management efficient NHS ? A year ago the BMJ cautiously welcomed the outcome of. 1984;289(November):1978\u20139."},{"issue":"8","key":"6383_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1001\/archinte.1988.00380080065018","volume":"148","author":"NZ Kerin","year":"1988","unstructured":"Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude, and Time Course of the Amiodarone-Warfarin Interaction. Arch Intern Med. 1988;148(8):1779\u201381.","journal-title":"Arch Intern Med"},{"issue":"7","key":"6383_CR30","first-page":"552","volume":"16","author":"RML Colunga Biancatelli","year":"2019","unstructured":"Colunga Biancatelli RML, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. Adverse reactions of amiodarone. J Geriatr Cardiol. 2019;16(7):552\u201366.","journal-title":"J Geriatr Cardiol"},{"key":"6383_CR31","doi-asserted-by":"publisher","unstructured":"Suh Y, Lee CJ, Cho DK, Cho YH, Shin DH, Ahn CM et al. Impact of National Health Checkup Service on Hard Atherosclerotic Cardiovascular Disease Events and All-Cause Mortality in the General Population. Am J Cardiol [Internet]. 2017;120(10):1804\u201312. Available from: https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.093","DOI":"10.1016\/j.amjcard.2017.07.093"},{"issue":"2","key":"6383_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/01.STR.0000053029.45352.A0","volume":"34","author":"S Bak","year":"2003","unstructured":"Bak S, Andersen M, Tsiropoulos I, Garc\u00eda Rodr\u00edguez LA, Hallas J, Christensen K, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke. 2003;34(2):379\u201385.","journal-title":"Stroke"},{"issue":"11","key":"6383_CR33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/archinte.168.11.1219","volume":"168","author":"MDM Haag","year":"2008","unstructured":"Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008;168(11):1219\u201324.","journal-title":"Arch Intern Med"},{"issue":"7","key":"6383_CR34","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1161\/STROKEAHA.107.508549","volume":"39","author":"CL Roumie","year":"2008","unstructured":"Roumie CL, Mitchel EF, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke. 2008;39(7):2037\u201345.","journal-title":"Stroke"},{"issue":"7","key":"6383_CR35","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/01.STR.0000226642.55207.94","volume":"37","author":"F Andersohn","year":"2006","unstructured":"Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37(7):1725\u201330.","journal-title":"Stroke"},{"issue":"September","key":"6383_CR36","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1136\/bmj.g5834","volume":"349","author":"J Wise","year":"2014","unstructured":"Wise J. NSAIDs are linked to increased risk of venous thromboembolism, study finds. BMJ. 2014;349(September):5834.","journal-title":"BMJ"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06383-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T12:06:20Z","timestamp":1686657980000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06383-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6383"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06383-2","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"28 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Boards of the Royal Thai Army Medical Department (approval number: M001h\/65). Informed consent was waivedby the Institutional Review Boards of the Royal Thai Army Medical Department owing to the retrospective electronic healthcare records in community hospitals. All methods were performed in accordance with the WMA Declaration of Helsinki\u2014ethics principles for medical research involving human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}